Cigna earnings beat by $0.04, revenue topped estimates
ROCKVILLE, Maryland - MaxCyte Inc. (NASDAQ: MXCT; LSE: MXCT), a cell-engineering company, disclosed a transaction by its Chief Financial Officer, Douglas Swirsky, involving the vesting of restricted stock units (RSUs) and subsequent sale of a portion of the shares. On March 18, 2025, Swirsky’s 20,313 RSUs vested, and to cover withholding tax obligations, 6,939 shares were sold at prices ranging from $3.140 to $3.215.
Following the transaction, Swirsky holds 13,374 shares of MaxCyte’s common stock, which represents approximately 2.2% of the company’s issued stock capital. He also retains 725,000 options, 98,437 RSUs, and 68,750 Performance Stock Units.
MaxCyte specializes in cell-based therapeutic technologies and offers the ExPERT platform, which includes instruments, disposables, software protocols, and a robust intellectual property portfolio. The company’s platforms support the development and commercialization of cell therapies.
The sale conducted by Swirsky was non-discretionary and was executed through the Nasdaq stock exchange on March 18, 2025. The transaction was reported in compliance with the UK Market Abuse Regulation.
This disclosure comes after a correction was issued to include the number of shares involved in the RSU vesting, which was initially omitted in a previous announcement. The corrected information was provided in a statement released by MaxCyte.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.